LEGN Projected Dividend Yield
ADS (Sponsored)/Legend Biotech Corp ( NASDAQ : LEGN )Legend Biotech is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Co.'s primary product candidate, ciltacabtagene autoleucel, or cilta-cel (referred to as LCAR- B38M for purposes of its LEGEND-2 trial), is a chimeric antigen receptor T cell (CAR-T) therapy it is jointly developing with its partner, Janssen Biotech, Inc. for the treatment of multiple myeloma. In addition to cilta-cel, Co. has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma. 20 YEAR PERFORMANCE RESULTS |
LEGN Dividend History Detail LEGN Dividend News LEGN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |